Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XSNX has been "the incredible shrinking machine" for investment cash. IMO.
Here it is.....
You are now in pure bash territory. Making statements, presuming intent that is negative...
I agree. Some event or indication may have precipitated this event. The ducks are lining up, IMO. We will see if it is the SEC log jam clearing...etc. Onward and upward....like Osiris....
"There are known knowns; there are things we know that we know.
There are known unknowns; that is to say, there are things that we now know we don't know.
But there are also unknown unknowns – there are things we do not know we don't know."
NBS probably would be fine pps wise if not for the report that their wonderful Vcel just aren't real.
I think Gary has the long term investor in mind, not the trader. If he was trying to appease the day trader, he would have signed a JV which would've popped the pps, temporarily, at the long term expense of the company's revenue creating potential. I'm not a day trader, so I see critical posts as coming from short term investors trying to flip it.
I could get better, if you're looking to buy...
Clarify something for me. Advanced Cell Tech says they won't partner the RPE program and other agree that it is too early (phase 1) to partner and get appropriate amounts of cash. But it is said there are strong expectations to partner the MSC and the platelet programs, and they aren't even approved for FDA trial phase 1 yet, so how does that expectation meet with reality?
I know we will miss Rocky's posts, I also have noticed that fordwill1953 has not posted for over a year... I always found fordwill1953 posts to be intelligent and educational.
Was there clarity as hinted at in a publication about the Vcel controversy?
PPS, there were 4 premarket trades, 10k each at .071, Setting the tone for the rest of the day.
These are some days of loss, Having lost Rocky, and in our family, my Cousin passed away yesterday from internal bleeding as a result of stage 4 pancreatic cancer....
ouch
www.rawstory.com/rs/2013/07/28/vatican-backed-vsel-alternative-to-stem-cells-found-to-be-a-fraud/
As noted many CEO's with promising biotech co. have failed to get FDA approval, maybe Rabin is just the maverick needed to break on through!
512,000 dollars/treatment....they can't compete with Advanced cell Technology...
Some notes from ACTC's recent patent application:
MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO
Page bookmark WO2013082543 (A1) - MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO
Inventor(s): LANZA ROBERT [US]; KIMBREL ERIN ANNE [US]; CHU JIANLIN [US]; KOURIS NICHOLAS ARTHUR [US] +
Applicant(s): ADVANCED CELL TECH INC [US] +
Int. Application number: PCT/US2012/067464
Priority number(s): US Provisional App: 61/565,358
Abstract
The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.
# of Claims: 125
[0243] In a further embodiment of the instant invention, a pharmaceutical preparation of the subject MSCs (e.g., generated by culturing hemangioblasts) is administered to a host for the treatment of autoimmune pathologies selected from the list comprising:
Acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome (APS), Autoimmune angioedema, Autoi mmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease, Autoimmune urticarial, Axonal & neuronal neuropathies, Balo disease, Behcet' s disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac disease, Chagas disease, Chronic fatigue syndrome, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cicatricial pemphigoid/benign mucosal pemphigoid, Crohn' s disease, Cogans syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST disease, Essential mixed cryoglobulinemia,
Demyelinating neuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Experimental allergic
encephalomyelitis, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Glomerulonephritis, Goodpasture' s syndrome, Granulomatosis with Polyangiitis (GPA) see Wegener's, Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis, Insulin-dependent diabetes (typel ), Interstitial cystitis, Juvenile arthritis, Juvenile diabetes, Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus (SLE), Lyme disease, chronic, Meniere's disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neuromyelitis optica (Devic's), Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome,
Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome,
Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatic, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon, Reflex sympathetic dystrophy, Reiter' s syndrome, Relapsing polychondritis, Restless legs syndrome, Retroperitoneal fibrosis, Rheumatic fever,
Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome, Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia, Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo, and Wegener's granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).
So why would you want to use MSCs from pluripotent stem cell source? Well the first reason of course is that you could have virtually unlimited numbers of these cells, off-the-shelf therapy. They're very, very easy to derive. They can be expanded in very, very large numbers. They're more youthful, coming from a pluripotent stem cell source, and they live a lot longer than the adult equivalent. So they have potentially greater efficacy, and I'll show you a little of that data, than the adult-derived cells. In fact, it turns out that when you try to get MSCs from say adult bone marrow and you expand it, after a few passages it serves as the great negative control, and even though it has all the same markers as an MSC, it loses its potency, so adult sources are very variable in their biological activity. But if you take a look at just the numbers, so if this is Wally that represents the number of MSCs you can get from one unit of bone marrow, if you start with the same unit from embryonic stem cell source, you can fill all of Fenway Park. So we can get over 30,000 fold greater expansion, so we can get just huge numbers of these cells, which allows us to really move into…we're now even contemplating going into horses. We can get such large numbers of these cells very, very easily. So that's great, we can get more of these cells.
Seems to me that when this patient improved from the 20/400 to 20/40, perhaps that is as good as he/she could possibly get, and for the finishing touches, a bit of lasik?
The mention of Glial cells recently by Rabin seems pretty interesting.
I recall that once the info is submitted to the journal, the timetable and publication is entirely in the hands of the publication.
I think ACTC RPE program will be approved by FDA, and I don't think it will require the completion of the phase III or II. FDA has already confirmed that all phases are not required to get approval, just convincing evidence of safety and effectiveness. No need to partner, really, unless a major company can prove that it will really make the pie bigger for all involved.
So they are backing off of the JV interest on RPE, it used to be that it wasn't JV ready because the trial was in phase 1, ok so how does that make another cell type eligible when no trial has been started for them, how can that be JV'd?
Ok, Thanks Rocky... that post does look familiar now that I see it again.
I don't know the history on this...ACTC Myoblast is approved for phase II. I see that it is for adult stem cells. Did they discontinue this because the adult stem cells just aren't commercially viable? Also, I wonder what they did for the phase 1.
The website for Ted Myles company, PrimeraDx
http://www.primeradx.com/senior-management.php
Securing shelf funds...Actc will have more flexibility with this type of funding which may or may not be accessed. But there is a need to have it there so they don't have to operate from a position of desperation. Speculation has it that it is part of a pretty good plan...leading to pretty big deals...as likely as anything.
Good news is ramping up from now on, IMO. Having a report of 20/400 go to 20/40 is just like a Super Bowl ring or Olympic Gold medal. This achievement won't go away. It validates the science beyond any doubt. Obviously if the patient has photoreceptors viable, boom they get rescued. The sooner this gets approved, the better for people in this condition, and the better for everyone.
Maybe the "with holding" of info is part of a sentiment where those with awarded shares can dump them at this low price, also those who are traders, then the reward comes to the longs who stick, the results, the rewards.
That's the first I saw....I'ts been about a month since the better vision had their first injection. If it was a 20/400, that would be from the better vision group, wouldn't it?
" One patient's vision went from 20/400 to 20/40, said Lanza."
Just wanted to amplify this sentence from the article!
It hasn't started yet, has it?
I think what Lanza has done is great and he is the face of the science. ACTC is also the holder of a large number of valuable patents and the current successful FDA trial. There is more than just one scientist, though. He is the great "quarterback" but their is a great team too.
When Al Gore said the public only knows about 1% of what happens in the Federal government, people always assume that it is the corruption they don't know about. Sometimes the actions of people in power are corrupt, sometimes they do things that aren't really bad, but to succeed they require an element of "decorum" outsiders do not understand. Share flippers and day traders are miffed. Longs see the light at the end of the tunnel. Time to put your big boy pants on and succeed even while discomfort presses upon you.
I'm sure the board is quite knowledgeable about the Form 4. I'm sure they could do without the "backseat" noise probably generated by anti ACTC board activists who'd like nothing better than to throw some sand into the gears.
There may be more or less to this, surviving extraordinary horrible times for financing, these actions pale in comparison to what big time money changers and congress has been doing for the past decade. I say just be happy there is a successful trial going on, sheesh. A revolution in the medical field. Chill out and celebrate the triumphs!
I recommend this stock to people I know, because the results of the RPE trial couldn't be better. I always say its a penny stock, but it's so much different than any other penny stock I've ever seen. The first members of the trial didn't just maintain improvements, but continued. And now the improvements include regaining color, do you know the difference between cones and rods functioning. Hello!
The reaction to ACTC good news and the subsequent dissatisfaction that always follows reminds me of my 4 year old. He was so happy when I bought him the pink car last night and today he is expressing his desire for the green one, now since the satisfaction over the red car has suddenly gone, mostly because he now wants that green one, even though it wasn't his choice last night.
Great, Thanks Chuckanutman!
So 150,000 has been approved and injected?